Last moves
Peptide Exchange
0molecules on your watchlist

Incretins

Oral semaglutide

Brand Wegovy pill

The first oral GLP-1 drug approved for weight management, cleared by the FDA on 22 December 2025 on the OASIS programme and SELECT. Earlier sold as Rybelsus for type 2 diabetes.

Oral semaglutide comes from Novo Nordisk and sits in the Incretins class on the board. Route: daily pill. Use tracked here: Weight management in adults with obesity or overweight with a related condition; cardiovascular risk reduction. It stands at Approved on the board, with 3 news moves logged; the latest is dated 2 Nov 2026.

  1. 05ApprovedHere now
  2. 04FiledApplication submitted to a regulator and under review.
  3. 03Phase 3Large confirmatory trials meant to support a filing.
  4. 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
  5. 01Phase 1First doses in people. Safety, dose range, how the body handles it.
Company
Novo Nordisk
Mechanism
GLP-1 receptor agonist peptide formulated as a daily tablet
Given as
daily pill
Lead use on the board
Weight management in adults with obesity or overweight with a related condition; cardiovascular risk reduction
Moves logged
3latest 1 day ago

Oral semaglutide news moves

  1. ▲ ReadoutHolds APP

    Wegovy pill prescriptions set a US weekly high as Lilly keeps its lead

    Weekly US scripts for Novo Nordisk's oral semaglutide rose 4.2% to a record 217,050. The count tracks demand, not sales, and the 38 abstracts lined up for November meetings carry no new efficacy results.

  2. ▼ SetbackNo stage

    Oral Wegovy in India stalls as CDSCO experts ask Novo Nordisk for local data

    India's endocrinology expert committee withheld permission for Novo Nordisk's semaglutide tablets and asked for an Indian bioequivalence study, Indian trial data and a SNAC rationale. The tablet is approved in the UK and EU, and no deadline was set.

  3. ▲ ExplainerHolds APP

    Oral semaglutide uptake reached injection levels within ten weeks of approval

    A JAMA Network Open research letter tracks nearly 48 million eligible US adults and finds new starts on the Wegovy pill briefly passed the semaglutide injection by March 2026. Tirzepatide stayed ahead, and about half of pill users were new to GLP-1 drugs.